ACM
NEO icon

AlphaCrest Capital Management’s NeoGenomics NEO Stock Holding History

AlphaCrest Capital Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,612
Closed -$264K – 751
2022
Q3 		$264K Buy
30,612
+17,008
+125% +$169K 0.02% 1176
2022
Q2 		$111K Sell
13,604
-2,920
-18% -$27.9K 0.01% 1231
2022
Q1 		$201K Buy
+16,524
New +$348K 0.01% 1208
2020
Q4 		– Sell
-19,300
Closed -$712K – 1223
2020
Q3 		$712K Buy
+19,300
New +$717K 0.08% 398
2020
Q2 		– Sell
-10,376
Closed -$286K – 1039
2020
Q1 		$286K Sell
10,376
-20,032
-66% -$600K 0.03% 815
2019
Q4 		$889K Buy
+30,408
New +$724K 0.07% 420

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCrest Capital Management's NEO Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of NeoGenomics (NEO) in Q4 2022, closing a stake of 30,612 shares — an estimated $264K sold.

AlphaCrest Capital Management first reported a position in NEO in Q4 2019 and held it in 6 quarters. The position peaked at $889K in Q4 2019. 244 funds tracked by Wall St. Rank hold NEO as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining NeoGenomics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 30,612 NeoGenomics shares in Q4 2022, an estimated $264K.
  • AlphaCrest Capital Management first reported a position in NeoGenomics in Q4 2019 and held it in 6 quarters.
  • AlphaCrest Capital Management's NeoGenomics position peaked at $889K in Q4 2019.
  • 244 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.